Sionna Therapeutics (NASDAQ:SION) Trading Up 5.8% – Should You Buy?

Sionna Therapeutics, Inc. (NASDAQ:SION) shares shot up 5.8% during trading on Thursday . The company traded as high as $39.25 and last traded at $39.0850. 121,745 shares were traded during trading, a decline of 59% from the average session volume of 298,613 shares. The stock had previously closed at $36.95.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Citigroup assumed coverage on shares of Sionna Therapeutics in a report on Tuesday, February 24th. They issued an “outperform” rating for the company. Wall Street Zen upgraded shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Lifesci Capital raised shares of Sionna Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 25th. UBS Group reiterated a “buy” rating on shares of Sionna Therapeutics in a report on Monday, March 2nd. Finally, BTIG Research reissued a “buy” rating and set a $58.00 target price on shares of Sionna Therapeutics in a report on Monday, March 2nd. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $50.57.

Sionna Therapeutics Stock Up 5.1%

The company has a 50 day moving average of $37.54 and a two-hundred day moving average of $37.68. The firm has a market cap of $1.75 billion, a P/E ratio of -19.92 and a beta of 3.01.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.15.

Insider Activity at Sionna Therapeutics

In other Sionna Therapeutics news, major shareholder Tpg Gp A, Llc sold 250,000 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $40.00, for a total value of $10,000,000.00. Following the transaction, the insider owned 6,494,962 shares of the company’s stock, valued at approximately $259,798,480. This represents a 3.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Orbimed Advisors Llc sold 29,063 shares of the stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $44.58, for a total value of $1,295,628.54. Following the sale, the director owned 3,530,702 shares of the company’s stock, valued at $157,398,695.16. This trade represents a 0.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 311,906 shares of company stock valued at $12,759,732 over the last ninety days. Insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Braidwell LP acquired a new position in shares of Sionna Therapeutics in the 2nd quarter valued at $18,770,000. Eventide Asset Management LLC acquired a new stake in Sionna Therapeutics during the 4th quarter worth about $26,290,000. Vanguard Group Inc. lifted its stake in Sionna Therapeutics by 81.4% during the third quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock valued at $33,620,000 after buying an additional 512,803 shares in the last quarter. State Street Corp lifted its stake in Sionna Therapeutics by 188.7% during the fourth quarter. State Street Corp now owns 693,395 shares of the company’s stock valued at $28,526,000 after buying an additional 453,196 shares in the last quarter. Finally, Viking Global Investors LP boosted its holdings in shares of Sionna Therapeutics by 8.2% in the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after buying an additional 242,427 shares during the period.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.